Cargando…

Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2

Aging and pre-existing conditions in older patients increase severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, although the causes remain unclear. Apart from acute pulmonary syndrome, Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Gilbert, Ali, Alysha, Takamatsu, Yoshiki, Wada, Ryoko, Masliah, Eliezer, Hashimoto, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997138/
https://www.ncbi.nlm.nih.gov/pubmed/33775925
http://dx.doi.org/10.1016/j.drudis.2021.03.013
_version_ 1783670259468730368
author Ho, Gilbert
Ali, Alysha
Takamatsu, Yoshiki
Wada, Ryoko
Masliah, Eliezer
Hashimoto, Makoto
author_facet Ho, Gilbert
Ali, Alysha
Takamatsu, Yoshiki
Wada, Ryoko
Masliah, Eliezer
Hashimoto, Makoto
author_sort Ho, Gilbert
collection PubMed
description Aging and pre-existing conditions in older patients increase severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, although the causes remain unclear. Apart from acute pulmonary syndrome, Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. Importantly, SARS-CoV-2 triggers de novo type 2 diabetes mellitus (T2DM) linked to age-associated cardiovascular disease (CVD), cancers, and neurodegeneration. Mechanistically, SARS-CoV-2 induces inflammation, possibly through damage-associated molecular pattern (DAMP) signaling and ‘cytokine storm,’ causing insulin resistance and the adiponectin (APN) paradox, a phenomenon linking metabolic dysfunction to chronic disease. Accordingly, preventing the APN paradox by suppressing APN-related inflammatory signaling might prove beneficial. A better understanding could uncover novel therapies for SARS-CoV-2 and its chronic disorders.
format Online
Article
Text
id pubmed-7997138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-79971382021-03-29 Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2 Ho, Gilbert Ali, Alysha Takamatsu, Yoshiki Wada, Ryoko Masliah, Eliezer Hashimoto, Makoto Drug Discov Today Post-Screen (Grey) Aging and pre-existing conditions in older patients increase severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, although the causes remain unclear. Apart from acute pulmonary syndrome, Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. Importantly, SARS-CoV-2 triggers de novo type 2 diabetes mellitus (T2DM) linked to age-associated cardiovascular disease (CVD), cancers, and neurodegeneration. Mechanistically, SARS-CoV-2 induces inflammation, possibly through damage-associated molecular pattern (DAMP) signaling and ‘cytokine storm,’ causing insulin resistance and the adiponectin (APN) paradox, a phenomenon linking metabolic dysfunction to chronic disease. Accordingly, preventing the APN paradox by suppressing APN-related inflammatory signaling might prove beneficial. A better understanding could uncover novel therapies for SARS-CoV-2 and its chronic disorders. Elsevier Ltd. 2021-08 2021-03-26 /pmc/articles/PMC7997138/ /pubmed/33775925 http://dx.doi.org/10.1016/j.drudis.2021.03.013 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Post-Screen (Grey)
Ho, Gilbert
Ali, Alysha
Takamatsu, Yoshiki
Wada, Ryoko
Masliah, Eliezer
Hashimoto, Makoto
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title_full Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title_fullStr Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title_full_unstemmed Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title_short Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
title_sort diabetes, inflammation, and the adiponectin paradox: therapeutic targets in sars-cov-2
topic Post-Screen (Grey)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997138/
https://www.ncbi.nlm.nih.gov/pubmed/33775925
http://dx.doi.org/10.1016/j.drudis.2021.03.013
work_keys_str_mv AT hogilbert diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2
AT alialysha diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2
AT takamatsuyoshiki diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2
AT wadaryoko diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2
AT masliaheliezer diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2
AT hashimotomakoto diabetesinflammationandtheadiponectinparadoxtherapeutictargetsinsarscov2